Kuihua Pharmaceutical

Kuihua Pharmaceutical Group Co., Ltd. is a large pharmaceutical group enterprise that integrates drug research and development, production, and sales, with a mission to 'make good medicine for the people, safeguard the healthy growth of Chinese children, and ensure the safety of medication for Chinese children'. Its headquarters is located in Harbin.
Founded in 2005, the group now has 26 subsidiaries, including 12 nationwide drug production enterprises, 5 pharmaceutical companies, 3 drug research institutes, 2 herbal medicine planting bases, and 1 pharmaceutical packaging materials company. Today, it ranks fifteenth among Chinese traditional Chinese medicine enterprises and has consistently been listed among the top 100 enterprises in China's pharmaceutical industry. It was listed on the Shenzhen Stock Exchange at the end of 2014, with stock code: 002737.
As a large-scale OTC enterprise with a 'dual brand umbrella', it adheres to leading with star brands, focusing on creating golden single products, and building a category cluster camp. It has made comprehensive layout in seven major fields: pediatric medication, gynecological medication, digestive system medication, respiratory and cold medication, rheumatism and bone injury medication, cardiovascular and cerebrovascular disease medication, and external medication. Currently, it holds 1,141 drug approval numbers and has over 300 marketed varieties, forming a well-structured product pipeline and developing a distinctive path from product, to brand, and then to category.